
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): May 25, 2017

Dimension Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

DELAWARE
(State or other jurisdiction
of incorporation)

001-37601
(Commission
File Number)

46-3942159
(I.R.S. Employer
Identification No.)

840 Memorial Drive, 4th Floor
Cambridge, MA
(Address of principal executive offices)

02139
(Zip Code)

Registrant's telephone number, including area code (617) 401-0011

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.07 Submission of Matters to a Vote of Security Holders.

At its Annual Meeting of Stockholders held on May 25, 2017 (the “Annual Meeting”), the stockholders of Dimension Therapeutics, Inc., a Delaware corporation (the “Company”) voted on the following matters, which are described in detail in the Company’s Proxy Statement filed with the U.S. Securities and Exchange Commission on April 14, 2017: (i) to elect one Class II director, namely Dr. Michael Dybbs, Ph.D., to hold office until the 2020 annual meeting of stockholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal (“Proposal 1”) and (ii) to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2017 (“Proposal 2”).

The Company’s stockholders approved the nominee recommended for election in Proposal 1 at the Annual Meeting.

Stockholders voted for directors as follows:

<u>Class II Director Nominee</u>	<u>For</u>	<u>Abstain/Withheld</u>	<u>Broker Non-Votes</u>
Michael Dybbs, Ph.D.	14,139,088	816,518	5,136,785

The Company’s stockholders approved Proposal 2. The votes cast at the Annual Meeting were as follows: 20,074,450 voted for, 16,449 shares voted against and 1,492 shares abstained from voting.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 26, 2017

DIMENSION THERAPEUTICS, INC.

By: /s/ Jean Franchi
Jean Franchi
Chief Financial Officer